Search Results - "LAIRD, Glen"

Beyond exposure‐response: A tutorial on statistical considerations in dose‐ranging studies by Laird, Glen, Xu, Lei, Liu, Meng, Liu, Jin

“…Dose‐ranging studies are a crucial part of the phase II drug development process. They complement the understanding gained from exposure‐response analyses…”
Get full text

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies by GILES, Francis, FISCHER, Thomas, KANTARJIAN, Hagop, DUGAN, Margaret, ALBITAR, Maher, BHALLA, Kapil, CORTES, Jorge, GARCIA-MANERO, Guillermo, BECK, Joachim, RAVANDI, Farhad, MASSON, Eric, RAE, Patricia, LAIRD, Glen, SHARMA, Sunil

“…Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589…”
Get full text

A Bayesian phase II proof‐of‐concept design for clinical trials with longitudinal endpoints by Zhang, Wen, Laird, Glen, Chen, Josh, Yuan, Ying

“…Existing phase II clinical trial designs focus on a single scalar endpoint, such as a binary, continuous, or survival endpoint. In some clinical trials, such…”
Get full text

Goodness-of-fit test for proportional subdistribution hazards model by Zhou, Bingqing, Fine, Jason, Laird, Glen

“…This paper concerns using modified weighted Schoenfeld residuals to test the proportionality of subdistribution hazards for the Fine–Gray model, similar to the…”
Get full text

Adaptive hybrid control design for comparative clinical trials with historical control data by Guo, Beibei, Laird, Glen, Song, Yang, Chen, Josh, Yuan, Ying

“…We propose an adaptive hybrid control causal (AHCC) design to leverage historical control data to reduce the sample size demanded by standard randomised…”
Get full text

Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting by Jazić, Ina, Liu, Xiaoyan, Laird, Glen

“…The drop-the-losers design combines a phase 2 trial of k treatments and a confirmatory phase 3 trial under a single adaptive protocol, thereby gaining…”
Get full text

A confirmatory basket design considering non-inferiority and superiority testing by Zhang, Yaohua, Chu, Chenghao, Beckman, Robert A., Gao, Lei, Laird, Glen, Yi, Bingming

“…For multiple rare diseases as defined by a common biomarker signature, or a disease with multiple disease subtypes of low frequency, it is often possible to…”
Get full text

Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies by Bresnick, Kathryn, Arteaga-Solis, Emilio, Millar, Stefanie J, Laird, Glen, LeCamus, Cecile

“…BackgroundCystic fibrosis (CF) is a genetic, multisystemic, progressive and life-shortening disease caused by mutations in the CF transmembrane conductance…”
Get full text

Burden of cystic fibrosis in children by Kathryn Bresnick, Emilio Arteaga-Solis, Stefanie J Millar, Glen Laird, Cecile LeCamus

“…Background Cystic fibrosis (CF) is a genetic, multisystemic, progressive and life-shortening disease caused by mutations in the CF transmembrane conductance…”
Get full text

Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification by Zhao, Yang, Zheng, Wei, Zhuo, Daisy Y., Lu, Yuefeng, Ma, Xiwen, Liu, Hengchang, Zeng, Zhen, Laird, Glen

“…Personalized medicine, or tailored therapy, has been an active and important topic in recent medical research. Many methods have been proposed in the…”
Get full text

Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat) by Zhang, Lei, Lebwohl, David, Masson, Eric, Laird, Glen, Cooper, Michael R, Prince, H Miles

Get full text

A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates by Bailey, Stuart, Neuenschwander, Beat, Laird, Glen, Branson, Michael

“…A Bayesian approach to finding the maximum tolerated dose (MTD) is presented. The approach is flexible, allowing inclusion of covariates, and enables…”
Get full text

A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) by Paschold, Eugene Henry, Mazieres, Julien, Lena, Hervé, Cruciani, Giorgio, Laird, Glen, Walters, Ian B., Chen, Allen C., Trifan, Ovidiu C.

“…Abstract only 7584 Background: CT- 322 is a pegylated protein engineered from the tenth type III human fibronectin domain thatspecifically blocks VEGFR-2…”
Get full text

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies by Ottmann, Oliver G., Spencer, Andrew, Prince, H. Miles, Bhalla, Kapil N., Fischer, Thomas, Liu, Angela, Parker, Kathryn, Jalaluddin, Muhammad, Laird, Glen, Woo, Margaret, Scott, Jeffrey W., DeAngelo, Daniel J.

“…Panobinostat (LBH589) is a novel and potent pan-deacetylase inhibitor (DACi) with broad preclinical activity in models of hematologic malignancies. This trial…”
Get full text

Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL) by Duvic, Madeleine, Becker, Jürgen C., Dalle, Stephane, Vanaclocha, Francisco, Bernengo, Maria Grazia, Lebbé, Celeste, Dummer, Reinhard, Hirawat, Samit, Zhang, Lei, Marshood, Miriam, Laird, Glen, Prince, H. Miles

“…Background: Panobinostat is a histone deacetylase inhibitor that has shown promising results in cutaneous T-cell lymphoma (CTCL). Objectives: An open-label,…”
Get full text

Psychiatric Comorbidity and Not Completing Jail-based Substance Abuse Treatment by Brady, Thomas M., Krebs, Christopher P., Laird, Glen

“…Many jail inmates have a history of mental illness, substance use, and drug-related crime. This article assesses the effect of psychiatric comorbidity on…”
Get full text

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies by Spencer, Andrew, Prince, Miles, DeAngelo, Daniel J., Fischer, Thomas, Bhalla, Kapil N., Giles, Francis J., Liu, Angela, Parker, Kathryn, Laird, Glen, Masson, Eric, Rediske, John, Scott, Jeffrey W., Ottmann, Oliver G.

“…LBH589 is a novel cinnamic acid hydroxamate DACi which induces apoptosis in multiple hematologic tumor cell lines in vitro at nanomolar levels. LBH589 has been…”
Get full text

A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies by Giles, Francis J., Fischer, Thomas, Cortes, Jorge, Beck, James, Ravandi-Kashani, Farhad, Garcia-Manero, Guillermo, Kantarjian, Hagop M., Peng, Bin, Rae, Patricia E., Laird, Glen, Sharma, Samil, Dugan, Margaret, Albitar, Maher, Bhalla, Kapil M.

“…LBH589 is a novel HDAC inhibitor which activates p21 and inhibits proliferation and induces apoptosis in tumor cell lines at nanomolar concentrations. In this…”
Get full text

Jail-Based Substance User Treatment: An Analysis of Retention by Krebs, Christopher P., Brady, Thomas, Laird, Glen

“…Many jail inmates have a history of substance use and "abuse"; few, however, receive comprehensive treatment for substance use disorders while in jail. The…”
Get full text

Nonparametric inference for the proportionality function in the random censorship model by Hollander, Myles, Laird, Glen, Song, Kai-Sheng

“…By generalizing the proportional hazards model, we introduce a new function β( t ), which we call the proportionality function, and which we show plays a role…”
Get full text